The efficacy and safety of Levemir® have been extensively studied and well established. The links below will provide you access to the published clinical data on PubMed.gov, the website of the US National Library of Medicine, National Institutes of Health.
Levemir® Clinical Studies
Type 2 Diabetes Clinical Studies
Blonde et al 2009 (TITRATE™)Blonde L, Merilainen M, Karwe V, Raskin P. Diabetes Obes Metab. 2009;11(6):623-631.
Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets; the TITRATE™ study
Hollander et al 2008 (NOVEL-2: Levemir® vs insulin glargine)Hollander P, Cooper J, Bregnhøj J, Pedersen CB. Clin Ther. 2008;30(11):1976-1987.
A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine U-100 in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes (Novel-2)
Rosenstock et al 2008 (Levemir® vs insulin glargine)Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. Diabetologia. 2008;51(3):408-416.
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine U-100 when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes
King 2009 (CGMS study in patients with T2DM; Levemir® vs insulin glargine)King AB. Diabetes Obes Metab. 2009;11(1):69-71.
Once-daily insulin detemir is comparable to once-daily insulin glargine U-100 in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study
Klein et al 2007 (Clamp study in patients with T2DM)Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Diabetes Obes Metab. 2007;9(3):290-299.
Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine U-100 in type 2 diabetes